Skip to content
Search

Latest Stories

How Has Technology Changed Contact Lenses?

Technological innovation has touched our lives in immeasurable ways, from city infrastructure to personal entertainment and beyond. Even our health and conditions have been improved by the right tech innovations; contact lenses were one such innovation, having been safely pioneered as recently as the 19th century. But there are more recent developments which could change the lives of contact lens users forever; what are they?

Smart Touch Contact Lenses


While Smart Touch lenses are a relatively simple innovation, it is often the simple innovations that have the most fundamental impact on contact lens users. Smart Touch lenses are a new type of contact lens produced with a breathable material to promote eye health throughout the day.

The key innovation lies in the packaging; Smart Touch contact lenses are provided in a bespoke blister packaging solution that delivers the lenses face-up. This ensures that the user never needs to touch the inner surface of the lens, keeping it hygienic and allowing for quick, unobtrusive application. These contact lenses provide innovative solutions for lens-wearers, and represent the power of slight technological improvements to existing products.

Miru 2022 07 14

Light-Adapting Contact Lenses

A key area for research and development in contact lenses is one that has already seen widespread usage by spectacles-wearers. Light-adaptive materials have been used in electronics and other technological innovations for decades, and the science is allowing materials to make use of this quality in smaller settings.

Light-adapting glasses are a popular product amongst those who wear glasses, protecting the eyes from sunlight and UV rays automatically. Development is underway to provide a form of contact lens that can provide the same benefits, without the need to wear glasses at all.

Antihistamine-Releasing Contact Lenses

Another innovation comes not from the world of material science, but instead from the field of medical science. Many contact-lens wearers are also allergy sufferers, with pollen and pet allergies alike causing significant discomfort for those wearing contacts.

Recently, contact lenses have been made commercially available that secrete antihistamines directly, allowing lens wearers to replace eye drops or pills with their regular daily contacts. These contacts represent a step change in the way those with poor vision can tend to their eye health, especially in allergy season.

Vision-Enhancing Contact Lenses

Seemingly coming from the world of science-fiction as opposed to verifiable science, there are also significant developments in the creation of a zoom-enabled contact lens. The proposed lens would be controlled via blinks, and enable the user to enhance their vision without the use of a separate device.

The concept may seem far-flung, but is much closer to a commercial reality than you may think; indeed, the first working prototype for such a lens was developed in 2015. This simple mechanical application heralds the introduction of significant, pie-in-the-sky contact lens designs to active development – indicating a bright and technologically-powered future for the contact lens industry.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less